Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 25;2(6):e83. doi: 10.1097/TXD.0000000000000595

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

PMC Copyright notice

Thymopoiesis and homeostatic proliferation. A, Typical example of the gating strategy: expression of CD31 within CD4+ and CD8+ naive (CCR7+CD45RO−) T cells. B, percentage of RTE; naive T cells expressing CD31, before and after alemtuzumab therapy, before and after alemtuzumab therapy. C, Typical example of the gating strategy of CD4+ and CD8+ Ki-67+ T cells. D, the percentage Ki-67 expressing T cells within the total CD4+, CD4+ naïve, CD4+ total memory and CD4+ central memory and effector memory T cells before and after alemtuzumab therapy. E, the percentage Ki-67 expressing T cells within the total CD8+, CD8+ naive, CD8+ total memory, and CD8+ effector memory and EMRA T cells before and after alemtuzumab therapy. F, The percentage of Ki-67+ Treg cell. Because of low number of cells, we could not determine the percentage RTE and Ki-67+ cells for all patients. Data are shown as median, *P < 0.05; significant differences comparing pretransplant values to posttransplant values using the Wilcoxon Signed-Rank test. RTE, recent thymic emigrants.